Clinical Trial Update: Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating neratinib for stage I-III HER2-mutated lobular breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Lobular Carcinoma of the Breast

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer | Phase 2 | Status: RECRUITING